Drug intelligence / Profile preview

cetuximab + pertuzumab

Development stage: Discontinued
Lead developer: National Cancer Institute
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Cetuximab + pertuzumab is a combination of two monoclonal antibodies targeting different aspects of the HER signaling pathway. Cetuximab binds to EGFR (HER1), preventing ligand binding and receptor activation, while pertuzumab binds to the dimerization domain (subdomain II) of HER2, blocking its heterodimerization with other HER family receptors. The combination was investigated for treatment of cetuximab-resistant KRAS wild-type metastatic colorectal cancer but was found to have intolerable toxicity despite showing some antitumor activity.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on cetuximab + pertuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cetuximab + pertuzumab.

Explore the full profile